{"data":{"id":481,"lang":"en","title":"Novavax Stock Surges 24% as Pfizer Deal and Earnings Beat Fuel Dramatic Turnaround","summary":"Novavax shares hit 52-week high on massive earnings beat and $530M Pfizer licensing deal for Matrix-M adjuvant technology.","category":"business","category_label":"Business","published_at":"2026-02-28T20:02:39Z","updated_at":"2026-02-28T20:02:39Z","url":"https://techtools.cz/tools/news/article/481-novavax-stock-surges-24-as-pfizer-deal-and-earnings-beat-fuel-dramatic","api_url":"https://techtools.cz/news-api/v1/articles/481?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/481.md?lang=en","image_url":"https://s.yimg.com/ny/api/res/1.2/6FVWg_eowOy5r4bPefFcZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMjAw/https://media.zenfs.com/en/stockstory_922/0bae6558fd4bdeaca75453a9d9554aed","word_count":159,"reading_time_minutes":1,"sources":[{"url":"https://ir.novavax.com/press-releases/2026-02-26-Novavax-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights","domain":"ir.novavax.com"},{"url":"https://finance.yahoo.com/news/why-novavax-nvax-stock-soaring-180433998.html","domain":"finance.yahoo.com"},{"url":"https://thedailyrecord.com/2026/02/26/novavax-raises-2026-revenue-forecast/","domain":"thedailyrecord.com"}],"translation":{"lang":"cs","id":482,"title":"Akcie Novavaxu vyskočily o 24 % díky dohodě s Pfizerem a překonání očekávání analytiků","url":"https://techtools.cz/tools/news/clanek/482-akcie-novavaxu-vyskocily-o-24-diky-dohode-s-pfizerem-a-prekonani-ocekavani","api_url":"https://techtools.cz/news-api/v1/articles/482?lang=cs"},"content":"Novavax shares soared 24.4% to hit a new 52-week high after the biotech reported fourth-quarter 2025 revenue of $147 million, crushing Wall Street estimates of $90 million by 63%. The company swung to a net profit of $18 million from a loss of $81 million a year earlier, marking a pivotal shift in its financial trajectory.\n\nThe turnaround is powered by two major deals: a $225 million milestone from Sanofi and a $530 million non-exclusive licensing agreement with Pfizer for Novavax's Matrix-M adjuvant technology signed in January 2026. Pfizer will use the adjuvant across up to two disease areas, with $30 million upfront and up to $500 million in additional milestones. Novavax raised its 2026 adjusted revenue guidance to $230-270 million, up sharply from its prior $185-205 million forecast.\n\nThe stock is now up 56% year-to-date. Analysts see the Matrix-M platform as a game-changer that validates Novavax's pivot from a COVID-focused vaccine maker to a broader biotech licensing powerhouse."}}